治疗诱导的脑组织坏死:神经肿瘤学中的临床挑战
本文是一篇关于脑部定向抗癌治疗所致脑组织坏死(治疗性坏死,TN)的综合综述。综述指出TN仍是一种特征不充分、诊断和治疗困难的疾病,常伴随显著的患者病残率,需更好地理解机制、改进诊断工具、开发预防策略并实施循证治疗实践。综述旨在梳理当前TN相关临床与研究实践的挑战,并提出待研究的问题和领域,以改善患者管理。
要点
- 治疗性坏死(TN)是脑部定向抗癌治疗的不良反应,诊断和治疗困难且常伴显著病残率。
- 需更好理解TN机制、改进诊断工具、开发预防策略并实施循证治疗实践。
- 综述梳理了TN相关临床与研究实践的现有挑战及待研究的问题。
核心结论
- 治疗性坏死仍是诊断和治疗困难的疾病,常伴显著患者病残率,需改善患者管理。
研究设计与样本
- 综合综述,检索范围原文未报告。
主要发现
- 脑部定向抗癌治疗的不良反应是神经肿瘤学的主要挑战,治疗性坏死仍是一种特征不充分的疾病。
- 治疗性坏死诊断和治疗困难,且常与显著的患者病残率相关。
- 更好地理解机制、改进诊断工具、开发预防策略和实施循证治疗实践对改善患者管理至关重要。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cancer therapy-induced adverse effects on the brain are a major challenge in neuro-oncology. Brain tissue necrosis (treatment necrosis [TN]) as a consequence of brain directed cancer therapy remains an insufficiently characterized condition with diagnostic and therapeutic difficulties and is frequently associated with significant patient morbidity. A better understanding of the underlying mechanisms, improvement of diagnostic tools, development of preventive strategies, and implementation of evidence-based therapeutic practices are pivotal to improve patient management. In this comprehensive review, we address existing challenges associated with current TN-related clinical and research practices and highlight unanswered questions and areas in need of further research with the ultimate goal to improve management of patients affected by this important neuro-oncological condition.
引用
- Winter SF, Loebel F, Loeffler J, et al. Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology. Neuro Oncol. 2019. PMID: 30828724. doi:10.1093/neuonc/noz048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。